Experimental and therapeutic opportunities for stem cells in multiple sclerosis

International Journal of Molecular Sciences

Volumn 13, Issue 11, 2012, Pages 14470-14491

  Patani, Rickie ^a,b   Chandran, Siddharthan ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Embryonic stem cells (ESCs); Induced pluripotent stem cells (iPSCs); Multiple sclerosis (MS); Neurodegenerative disease; Pluripotent stem cells (PSCs)

Indexed keywords

AXONAL INJURY; CELL FATE; CELL POPULATION; CELL REGENERATION; DEMYELINATION; DISEASE ACTIVITY; DISEASE MODEL; EMBRYONIC STEM CELL; HUMAN; MULTIPLE SCLEROSIS; NERVE CELL DIFFERENTIATION; NEUROPROTECTION; NONHUMAN; NUCLEAR REPROGRAMMING; OLIGODENDROGLIA; PATHOPHYSIOLOGY; PLURIPOTENT STEM CELL; REMYELINIZATION; REVIEW; STEM CELL TRANSPLANTATION; THERAPY EFFECT; ANIMAL; BIOLOGICAL THERAPY; CYTOLOGY; STEM CELL;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; DISEASE MODELS, ANIMAL; HUMANS; MULTIPLE SCLEROSIS; PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84870681930     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131114470     Document Type: Review

References (157)

1. Compston, A.; Coles, A. Multiple sclerosis. Lancet 2002, 359, 1221-1231.
2. Ferguson, B.; Matyszak, M.K.; Esiri, M.M.; Perry, V.H. Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120, 393-399.
3. Bjartmar, C.; Kidd, G.; Mörk, S.; Rudick, R.; Trapp, B.D. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol. 2000, 48, 893-901.
4. Trapp, B.D.; Peterson, J.; Ransohoff, R.M.; Rudick, R.; Mörk, S.; Bö, L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338, 278-285.
5. Simon, J.H. From enhancing lesions to brain atrophy in relapsing MS. J. Neuroimmunol. 1999, 98, 7-15.
6. Fisher, E.; Rudick, R.A.; Simon, J.H.; Cutter, G.; Baier, M.; Lee, J.-C.; Miller, D.; Weinstock-Guttman, B.; Mass, M.K.; Dougherty, D.S.; et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002, 59, 1412-1420.
7. Evangelou, N.; Esiri, M.M.; Smith, S.; Palace, J.; Matthews, P.M. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann. Neurol. 2000, 47, 391-395.
8. Sawcer, S.; Hellenthal, G.; Pirinen, M.; Spencer, C.C.; Patsopoulos, N.A.; Moutsianas, L.; Dilthey, A.; Su, Z.; Freeman, C.; Hunt, S.E.; et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476, 214-219.
9. Raff, M.C.; Whitmore, A.V.; Finn, J.T. Axonal self-destruction and neurodegeneration. Science 2002, 296, 868-871.
10. Chandran, S.; Hunt, D.; Joannides, A.; Zhao, C.; Compston, A.; Franklin, R.J. Myelin repair: The role of stem and precursor cells in multiple sclerosis. Philos. Trans. R. Soc. B 2008, 363, 171-183.
11. Raine, C.S.; Cross, A.H. Axonal dystrophy as a consequence of long-term demyelination. Lab. Invest. 1989, 60, 714-725.
12. Kornek, B.; Storch, M.K.; Weissert, R.; Wallstroem, E.; Stefferl, A.; Olsson, T.; Linington, C.; Schmidbauer, M.; Lassmann, H. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 2000, 157, 267-276.
13. Rodriguez, M. A function of myelin is to protect axons from subsequent injury: Implications for deficits in multiple sclerosis. Brain 2003, 126, 751-752.
14. Patrikios, P.; Stadelmann, C.; Kutzelnigg, A.; Rauschka, H.; Schmidbauer, M.; Laursen, H.; Sorensen, P.S.; Brück, W.; Lucchinetti, C.; Lassmann, H. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006, 129, 3165-3472.
15. Patani, R.; Balaratnam, M.; Vora, A.; Reynolds, R. Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropathol. Appl. Neurobiol. 2007, 33, 277-287.
16. Blakemore, W.F. Pattern of remyelination in the CNS. Nature 1974, 249, 577-578.
17. Ludwin, S.K.; Maitland, M. Long-term remyelination fails to reconstitute normal thickness of central myelin sheaths. J. Neurol. Sci. 1984, 64, 193-198.
18. Jeffery, N.D.; Blakemore, W.F. Locomotor deficits induced by experimental spinal cord demyelination are abolished by spontaneous remyelination. Brain 1997, 120, 27-37.
19. Liebetanz, D.; Merkler, D. Effects of commissural de-and remyelination on motor skill behaviour in the cuprizone mouse model of multiple sclerosis. Exp. Neurol. 2006, 202, 217-224.
20. Felts, P.A.; Baker, T.A.; Smith, K.J. Conduction in segmentally demyelinated mammalian central axons. J. Neurosci. 1997, 17, 7267-7277.
21. Craner, M.J.; Newcombe, J.; Black, J.A.; Hartle, C.; Cuzner, M.L.; Waxman, S.G. Molecular changes in neurons in multiple sclerosis: Altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc. Natl. Acad. Sci. USA 2004, 101, 8168-8173.
22. Colello, R.J.; Pott, U.; Schwab, M.E. The role of oligodendrocytes and myelin on axon maturation in the developing rat retinofugal pathway. J. Neurosci. 1994, 14, 2594-2605.
23. Sánchez, I.; Hassinger, L.; Paskevich, P.A.; Shine, H.D.; Nixon, R.A. Oligodendroglia regulate the regional expansion of axon caliber and local accumulation of neurofilaments during development independently of myelin formation. J. Neurosci. 1996, 16, 5095-5105.
24. Witt, A.; Brady, S.T. Unwrapping new layers of complexity in axon/glial relationships. Glia 2000, 29, 112-117.
25. Kaplan, M.R.; Cho, M.H.; Ullian, E.M.; Isom, L.L.; Levinson, S.R.; Barres, B.A. Differential control of clustering of the sodium channels Na(v)1.2 and Na(v)1.6 at developing CNS nodes of Ranvier. Neuron 2001, 30, 105-119.
26. Kaplan, M.R.; Meyer-Franke, A.; Lambert, S.; Bennett, V.; Duncan, I.D.; Levinson, S.R.; Barres, B.A. Induction of sodium channel clustering by oligodendrocytes. Nature 1997, 386, 724-728.
27. Waxman, S.G. Acquired channelopathies in nerve injury and MS. Neurology 2001, 56, 1621-1627.
28. Wilkins, A.; Compston, A. Trophic factors attenuate nitric oxide mediated neuronal and axonal injury in vitro: Roles and interactions of mitogen-activated protein kinase signalling pathways. J. Neurochem. 2005, 92, 1487-1496.
29. Wilkins, A.; Majed, H.; Layfield, R.; Compston, A.; Chandran, S. Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: A novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor. J. Neurosci. 2003, 23, 4967-4974.
30. Wilkins, A.; Chandran, S.; Compston, A. A role for oligodendrocyte-derived IGF-1 in trophic support of cortical neurons. Glia 2001, 36, 48-57.
31. Lappe-Siefke, C.; Goebbels, S.; Gravel, M.; Nicksch, E.; Lee, J.; Braun, P.E.; Griffiths, I.R.; Nave, K.A. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat. Genet. 2003, 33, 366-374.
32. Griffiths, I.; Klugmann, M.; Anderson, T.; Yool, D.; Thomson, C.; Schwab, M.H.; Schneider, A.; Zimmermann, F.; McCulloch, M.; Nadon, N.; et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 1998, 280, 1610-1613.
33. Scherer, S. Axonal pathology in demyelinating diseases. Ann. Neurol. 1999, 45, 6-7.
34. Doetsch, F.; Hen, R. Young and excitable: The function of new neurons in the adult mammalian brain. Curr. Opin. Neurobiol. 2005, 15, 121-128.
35. Reynolds, B.A.; Tetzlaff, W.; Weiss, S. A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J. Neurosci. 1992, 12, 4565-4574.
36. Reynolds, B.A.; Weiss, S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992, 255, 1707-1710.
37. Carroll, W.M.; Jennings, A.R. Early recruitment of oligodendrocyte precursors in CNS demyelination. Brain 1994, 117, 563-578.
38. Gensert, J.M.; Goldman, J.E. Endogenous progenitors remyelinate demyelinated axons in the adult CNS. Neuron 1997, 19, 197-203.
39. Horner, P.J.; Power, A.E.; Kempermann, G.; Kuhn, H.G.; Palmer, T.D.; Winkler, J.; Thal, L.J.; Gage, F.H. Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord. J. Neurosci. 2000, 20, 2218-2228.
40. Watanabe, M.; Toyama, Y.; Nishiyama, A. Differentiation of proliferated NG2-positive glial progenitor cells in a remyelinating lesion. J. Neurosci. Res. 2002, 69, 826-836.
41. Zhang, S.C.; Ge, B.; Duncan, I.D. Adult brain retains the potential to generate oligodendroglial progenitors with extensive myelination capacity. Proc. Natl. Acad. Sci. USA 1999, 96, 4089-4094.
42. Windrem, M.S.; Roy, N.S.; Wang, J.; Nunes, M.; Benraiss, A.; Goodman, R.; McKhann, G.M., II; Goldman, S.A. Progenitor cells derived from the adult human subcortical white matter disperse and differentiate as oligodendrocytes within demyelinated lesions of the rat brain. J. Neurosci. Res. 2002, 69, 966-975.
43. Franklin, R.J. Why does remyelination fail in multiple sclerosis? Nat. Rev. Neurosci. 2002, 3, 705-714.
44. Chari, D.M.; Blakemore, W.F. Efficient recolonisation of progenitor-depleted areas of the CNS by adult oligodendrocyte progenitor cells. Glia 2002, 37, 307-313.
45. Penderis, J.; Shields, S.A.; Franklin, R.J. Impaired remyelination and depletion of oligodendrocyte progenitors does not occur following repeated episodes of focal demyelination in the rat central nervous system. Brain 2003, 126, 1382-1391.
46. Ludwin, S.K. Chronic demyelination inhibits remyelination in the central nervous system. An analysis of contributing factors. Lab. Invest. 1980, 43, 382-387.
47. Mason, J.L.; Toews, A.; Hostettler, J.D.; Morell, P.; Suzuki, K.; Goldman, J.E.; Matsushima, G.K. Oligodendrocytes and progenitors become progressively depleted within chronically demyelinated lesions. Am. J. Pathol. 2004, 164, 1673-1682.
48. Franklin, R.J.; Ffrench-Constant, C. Remyelination in the CNS: From biology to therapy. Nat. Rev. Neurosci. 2008, 9, 839-855.
49. Niehaus, A.; Shi, J.; Grzenkowski, M.; Diers-Fenger, M.; Archelos, J.; Hartung, H.P.; Toyka, K.; Brück, W.; Trotter, J. Patients with active relapsing-remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: Implications for remyelination. Ann. Neurol. 2000, 48, 362-371.
50. Williams, A.; Piaton, G.; Aigrot, M.S.; Belhadi, A.; Théaudin, M.; Petermann, F.; Thomas, J.L.; Zalc, B.; Lubetzki, C. Semaphorin 3A and 3F: Key players in myelin repair in multiple sclerosis? Brain 2007, 130, 2554-2565.
51. Wolswijk, G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J. Neurosci. 1998, 18, 601-609.
52. Chang, A.; Tourtellotte, W.W.; Rudick, R.; Trapp, B.D. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 2002, 346, 165-173.
53. Chang, A.; Nishiyama, A.; Peterson, J.; Prineas, J.; Trapp, B.D. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J. Neurosci. 2000, 20, 6404-6412.
54. Kuhlmann, T.; Miron, V.; Cui, Q.; Wegner, C.; Antel, J.; Brück, W. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 2008, 131, 1749-1758.
55. Kotter, M.R.; Li, W.-W.; Zhao, C.; Franklin, R.J.M. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J. Neurosci. 2006, 26, 328-332.
56. Kotter, M.R.; Zhao, C.; van Rooijen, N.; Franklin, R.J. Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol. Dis. 2005, 18, 166-175.
57. Shields, S.A.; Gilson, J.M.; Blakemore, W.F.; Franklin, R.J. Remyelination occurs as extensively but more slowly in old rats compared to young rats following gliotoxin-induced CNS demyelination. Glia 1999, 28, 77-83.
58. Charles, P.; Reynolds, R.; Seilhean, D.; Rougon, G.; Aigrot, M.S.; Niezgoda, A.; Zalc, B.; Lubetzki, C. Re-expression of PSA-NCAM by demyelinated axons: An inhibitor of remyelination in multiple sclerosis? Brain 2002, 125, 1972-1979.
59. Charles, P.; Hernandez, M.P.; Stankoff, B.; Aigrot, M.S.; Colin, C.; Rougon, G.; Zalc, B.; Lubetzki, C. Negative regulation of central nervous system myelination by polysialylated-neural cell adhesion molecule. Proc. Natl. Acad. Sci. USA 2000, 97, 7585-7590.
60. Redwine, J.M.; Armstrong, R.C. In vivo proliferation of oligodendrocyte progenitors expressing PDGFalphaR during early remyelination. J. Neurobiol. 1998, 37, 413-428.
61. Williams, A.; Piaton, G.; Lubetzki, C. Astrocytes-Friends or foes in multiple sclerosis? Glia 2007, 55, 1300-1312.
62. Albrecht, P.J.; Murtie, J.C.; Ness, J.K.; Redwine, J.M.; Enterline, J.R.; Armstrong, R.C.; Levison, S.W. Astrocytes produce CNTF during the remyelination phase of viral-induced spinal cord demyelination to stimulate FGF-2 production. Neurobiol. Dis. 2003, 13, 89-101.
63. Li, W.W.; Penderis, J.; Zhao, C.; Schumacher, M.; Franklin, R.J. Females remyelinate more efficiently than males following demyelination in the aged but not young adult CNS. Exp. Neurol. 2006, 202, 250-254.
64. Bieber, A.J.; Ure, D.R.; Rodriguez, M. Genetically dominant spinal cord repair in a murine model of chronic progressive multiple sclerosis. J. Neuropathol. Exp. Neurol. 2005, 64, 46-57.
65. Barnett, M.H.; Prineas, J.W. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann. Neurol. 2004, 55, 458-468.
66. Anderson, J.M.; Patani, R.; Reynolds, R.; Nicholas, R.; Compston, A.; Spillantini, M.G.; Chandran, S. Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis. Acta Neuropathol. 2009, 117, 583-589.
67. Anderson, J.M.; Hampton, D.W.; Patani, R.; Pryce, G.; Crowther, R.A.; Reynolds, R.; Franklin, R.J.; Giovannoni, G.; Compston, D.A.; Baker, D.; et al. Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis. Brain 2008, 131, 1736-1748.
68. Anderson, J.M.; Patani, R.; Reynolds, R.; Nicholas, R.; Compston, A.; Spillantini, M.G.; Chandran, S. Abnormal tau phosphorylation in primary progressive multiple sclerosis. Acta Neuropathol. 2010, 119, 591-600.
69. Huang, J.K.; Jarjour, A.A.; Oumesmar, B.N.; Kerninon, C.; Williams, A.; Krezel, W.; Kagechika, H.; Bauer, J.; Zhao, C.; Evercooren, A.B.; et al. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat. Neurosci. 2011, 14, 45-53.
70. Rouiller, E.M.; Moret, V.; Tanne, J.; Boussaoud, D. Evidence for direct connections between the hand region of the supplementary motor area and cervical motoneurons in the macaque monkey. Eur. J. Neurosci. 1996, 8, 1055-1059.
71. Lemon, R.N.; Kirkwood, P.A.; Maier, M.A.; Nakajima, K.; Nathan, P. Direct and indirect pathways for corticospinal control of upper limb motoneurons in the primate. Prog. Brain Res. 2004, 143, 263-279.
72. Lemon, R.N.; Griffiths, J. Comparing the function of the corticospinal system in different species: organizational differences for motor specialization? Muscle Nerve 2005, 32, 261-279.
73. Zhang, S.C. Neural subtype specification from embryonic stem cells. Brain Pathol. 2006, 16, 132-142.
74. Dermitzakis, E.T.; Clark, A.G. Evolution of transcription factor binding sites in Mammalian gene regulatory regions: Conservation and turnover. Mol. Biol. Evol. 2002, 19, 1114-1121.
75. Papadia, S.; Soriano, F.X.; Léveillé, F.; Martel, M.A.; Dakin, K.A.; Hansen, H.H.; Kaindl, A.; Sifringer, M.; Fowler, J.; Stefovska, V.; et al. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat. Neurosci. 2008, 11, 476-487.
76. Hardingham, G.E.; Patani, R.; Baxter, P.; Wyllie, D.J.; Chandran, S. Human embryonic stem cell-derived neurons as a tool for studying neuroprotection and neurodegeneration. Mol. Neurobiol. 2010, 42, 97-102.
77. Yellon, D.M.; Hausenloy, D.J. Myocardial reperfusion injury. N. Engl. J. Med. 2007, 357, 1121-1135.
78. Dirksen, M.T.; Laarman, G.J.; Simoons, M.L.; Duncker, D.J. Reperfusion injury in humans: A review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc. Res. 2007, 74, 343-355.
79. Shuaib, A.; Lees, K.R.; Lyden, P.; Grotta, J.; Davalos, A.; Davis, S.M.; Diener, H.C.; Ashwood, T.; Wasiewski, W.W.; et al. NXY-059 for the treatment of acute ischemic stroke. N. Engl. J. Med. 2007, 357, 562-571.
80. Besselink, M.G.; van Santvoort, H.C.; Buskens, E.; Boermeester, M.A.; van Goor, H.; Timmerman, H.M.; Nieuwenhuijs, V.B.; Bollen, T.L.; van Ramshorst, B.; Witteman, B.J.; et al. Probiotic prophylaxis in predicted severe acute pancreatitis: A randomised, double-blind, placebo-controlled trial. Lancet 2008, 371, 651-659.
81. Han, S.S.; Williams, L.A.; Eggan, K.C. Constructing and deconstructing stem cell models of neurological disease. Neuron 2011, 70, 626-644.
82. Thomson, J.A.; Itskovitz-Eldor, J.; Shapiro, S.S.; Waknitz, M.A.; Swiergiel, J.J.; Marshall, V.S.; Jones, J.M. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282, 1145-1147.
83. Li, X.J.; Du, Z.W.; Zarnowska, E.D.; Pankratz, M.; Hansen, L.O.; Pearce, R.A.; Zhang, S.C. Specification of motoneurons from human embryonic stem cells. Nat. Biotechnol. 2005, 23, 215-221.
84. Schulz, T.C.; Noggle, S.A.; Palmarini, G.M.; Weiler, D.A.; Lyons, I.G.; Pensa, K.A.; Meedeniya, A.C.; Davidson, B.P.; Lambert, N.A.; Condie, B.G. Differentiation of human embryonic stem cells to dopaminergic neurons in serum-free suspension culture. Stem Cells 2004, 22, 1218-1238.
85. Perrier, A.L.; Tabar, V.; Barberi, T.; Rubio, M.E.; Bruses, J.; Topf, N.; Harrison, N.L.; Studer, L. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc. Natl. Acad. Sci. USA 2004, 101, 12543-12548.
86. Li, X.J.; Hu, B.Y.; Jones, S.A.; Zhang, Y.S.; Lavaute, T.; Du, Z.W.; Zhang, S.C. Directed differentiation of ventral spinal progenitors and motor neurons from human embryonic stem cells by small molecules. Stem Cells 2008, 26, 886-893.
87. Eiraku, M.; Watanabe, K.; Matsuo-Takasaki, M.; Kawada, M.; Yonemura, S.; Matsumura, M.; Wataya, T.; Nishiyama, A.; Muguruma, K.; Sasai, Y. Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. Cell Stem Cell 2008, 3, 519-532.
88. Patani, R.; Compston, A.; Puddifoot, C.A.; Wyllie, D.J.A.; Hardingham, G.E.; Allen, N.D.; Chandran, S. Activin/nodal inhibition alone accelerates highly efficient neural conversion from human embryonic stem cells and imposes a caudal positional identity. PLoS One 2009, 4, e7327.
89. Patani, R.; Hollins, A.J.; Wishart, T.M.; Puddifoot, C.A.; Álvarez, S.; de Lera, A.R.; Wyllie, D.J.A.; Compston, D.A.S.; Pedersen, R.A.; Gillingwater, T.H.; et al. Retinoid-independent motor neurogenesis from human embryonic stem cells reveals a medial columnar ground state. Nat. Commun. 2011, 2, 214.
90. Krencik, R.; Weick, J.P.; Liu, Y.; Zhang, Z.-J.; Zhang, S.-C. Specification of transplantable astroglial subtypes from human pluripotent stem cells. Nat. Biotechnol. 2011, 29, 528-534.
91. Gupta, K.; Patani, R.; Baxter, P.; Serio, A.; Story, D.; Tsujita, T.; Hayes, J.D.; Pedersen, R.A.; Hardingham, G.E.; Chandran, S. Human embryonic stem cell derived astrocytes mediate non-cell-autonomous neuroprotection through endogenous and drug-induced mechanisms. Cell Death Differ. 2012, 19, 779-787.
92. Nistor, G.I.; Totoiu, M.O.; Haque, N.; Carpenter, M.K.; Keirstead, H.S. Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation. Glia 2005, 49, 385-396.
93. Keirstead, H.S.; Nistor, G.; Bernal, G.; Totoiu, M.; Cloutier, F.; Sharp, K.; Steward, O. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J. Neurosci. 2005, 25, 4694-4705.
94. Faulkner, J.; Keirstead, H.S. Human embryonic stem cell-derived oligodendrocyte progenitors for the treatment of spinal cord injury. Transpl. Immunol. 2005, 15, 131-142.
95. Hu, B.Y.; Du, Z.W.; Li, X.J.; Ayala, M.; Zhang, S.C. Human oligodendrocytes from embryonic stem cells: Conserved SHH signaling networks and divergent FGF effects. Development 2009, 136, 1443-1452.
96. Okita, K.; Ichisaka, T.; Yamanaka, S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448, 313-317.
97. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131, 861-872.
98. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126, 663-676.
99. Majed, H.H.; Chandran, S.; Niclou, S.P.; Nicholas, R.S.; Wilkins, A.; Wing, M.G.; Rhodes, K.E.; Spillantini, M.G.; Compston, A. A novel role for Sema3A in neuroprotection from injury mediated by activated microglia. J. Neurosci. 2006, 26, 1730-1738.
100. Amit, M.; Margulets, V.; Segev, H.; Shariki, K.; Laevsky, I.; Coleman, R.; Itskovitz-Eldor, J. Human feeder layers for human embryonic stem cells. Biol. Reprod. 2003, 68, 2150-2156.
101. Amit, M.; Shariki, C.; Margulets, V.; Itskovitz-Eldor, J. Feeder layer-and serum-free culture of human embryonic stem cells. Biol. Reprod. 2004, 70, 837-845.
102. Xu, C.; Inokuma, M.S.; Denham, J.; Golds, K.; Kundu, P.; Gold, J.D.; Carpenter, M.K. Feeder-free growth of undifferentiated human embryonic stem cells. Nat. Biotechnol. 2001, 19, 971-974.
103. Vallier, L.; Pedersen, R. Differentiation of human embryonic stem cells in adherent and in chemically defined culture conditions. Curr. Protoc. Stem Cell Biol. 2008, doi:10.1002/9780470151808.sc01d04s4.
104. Joannides, A.J.; Fiore-Hériché, C.; Battersby, A.A.; Athauda-Arachchi, P.; Bouhon, I.A.; Williams, L.; Westmore, K.; Kemp, P.J.; Compston, A.; Allen, N.D.; et al. A scaleable and defined system for generating neural stem cells from human embryonic stem cells. Stem Cells 2007, 25, 731-737.
105. Gurdon, J.B.; Elsdale, T.R.; Fischberg, M. Sexually mature individuals of Xenopus laevis from the transplantation of single somatic nuclei. Nature 1958, 182, 64-65.
106. Campbell, K.H.; McWhir, J.; Ritchie, W.A.; Wilmut, I. Sheep cloned by nuclear transfer from a cultured cell line. Nature 1996, 380, 64-66.
107. Cowan, C.A.; Atienza, J.; Melton, D.A.; Eggan, K. Nuclear reprogramming of somatic cells after fusion with human embryonic stem cells. Science 2005, 309, 1369-1373.
108. Maherali, N.; Hochedlinger, K. Tgfbeta signal inhibition cooperates in the induction of iPSCs and replaces Sox2 and cMyc. Curr. Biol. 2009, 19, 1718-1723.
109. Lin, T.; Ambasudhan, R.; Yuan, X.; Li, W.; Hilcove, S.; Abujarour, R.; Lin, X.; Hahm, H.S.; Hao, E.; Hayek, A.; Ding, S. A chemical platform for improved induction of human iPSCs. Nat. Methods 2009, 6, 805-808.
110. Abujarour, R.; Ding, S. Induced pluripotent stem cells free of exogenous reprogramming factors. Genome Biol. 2009, 10, 220.
111. Vierbuchen, T.; Ostermeier, A.; Pang, Z.P.; Kokubu, Y.; Südhof, T.C.; Wernig, M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010, 463, 1035-1041.
112. Caiazzo, M.; Dell'Anno, M.T.; Dvoretskova, E.; Lazarevic, D.; Taverna, S.; Leo, D.; Sotnikova, T.D.; Menegon, A.; Roncaglia, P.; Colciago, G.; et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 2011, 476, 224-227.
113. Lee, H.; Shamy, G.A.; Elkabetz, Y.; Schofield, C.M.; Harrsion, N.L.; Panagiotakos, G.; Socci, N.D.; Tabar, V.; Studer, L. Directed differentiation and transplantation of human embryonic stem cell-derived motoneurons. Stem Cells 2007, 25, 1931-1939.
114. Li, X.J.; Zhang, X.; Johnson, M.A.; Wang, Z.B.; Lavaute, T.; Zhang, S.C. Coordination of sonic hedgehog and Wnt signaling determines ventral and dorsal telencephalic neuron types from human embryonic stem cells. Development 2009, 136, 4055-4063.
115. Patani, R.; Lewis, P.A.; Trabzuni, D.; Puddifoot, C.A.; Wyllie, D.J.; Walker, R.; Smith, C.; Hardingham, G.E.; Weale, M.; Hardy, J.; et al. Investigating the utility of human embryonic stem cell-derived neurons to model ageing and neurodegenerative disease using whole-genome gene expression and splicing analysis. J. Neurochem. 2012, 122, 738-751.
116. Wichterle, H.; Przedborski, S. What can pluripotent stem cells teach us about neurodegenerative diseases? Nat. Neurosci. 2010, 13, 800-804.
117. Ebert, A.D.; Yu, J.; Rose, F.F., Jr.; Mattis, V.B.; Lorson, C.L.; Thomson, J.A.; Svendsen, C.N. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457, 277-280.
118. Lee, G.; Papapetrou, E.P.; Kim, H.; Chambers, S.M.; Tomishima, M.J.; Fasano, C.A.; Ganat, Y.M.; Menon, J.; Shimizu, F.; Viale, A.; et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009, 461, 402-406.
119. Marchetto, M.C.; Carromeu, C.; Acab, A.; Yu, D.; Yeo, G.W.; Mu, Y.; CHen, G.; Gage, F.H.; Muotri, A.R. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010, 143, 527-539.
120. Nguyen, H.N.; Byers, B.; Cord, B.; Shcheglovitov, A.; Byrne, J.; Gujar, P.; Kee, K.; Schüle, B.; Dolmetsch, R.E.; Langston, W.; et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 2011, 8, 267-280.
121. Bilican, B.; Serio, A.; Barmada, S.J.; Nishimura, A.L.; Sullivan, G.J.; Carrasco, M.; Phatnani, H.P.; Puddifoot, C.A.; Story, D.; Fletcher, J.; et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc. Natl. Acad. Sci. USA 2012, 109, 5803-5808.
122. Murray, K.; Dubois-Dalcq, M. Emergence of oligodendrocytes from human neural spheres. J. Neurosci. Res. 1997, 50, 146-156.
123. Quinn, S.M.; Walters, W.M.; Vescovi, A.L.; Whittemore, S.R. Lineage restriction of neuroepithelial precursor cells from fetal human spinal cord. J. Neurosci. Res. 1999, 57, 590-602.
124. Zhang, S.C.; Ge, B.; Duncan, I.D. Tracing human oligodendroglial development in vitro. J. Neurosci. Res. 2000, 59, 421-429.
125. Chandran, S.; Compston, A.; Jauniaux, E.; Gilson, J.; Blakemore, W.; Svendsen, C. Differential generation of oligodendrocytes from human and rodent embryonic spinal cord neural precursors. Glia 2004, 47, 314-324.
126. Zou, J.; Maeder, M.L.; Mali, P.; Pruett-Miller, S.M.; Thibodeau-Beganny, S.; Chou, B.K.; Chen, G.; Ye, Z.; Park, I.H.; Dalye, G.Q.; et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 2009, 5, 97-110.
127. Zou, J.; Mali, P.; Huang, X.; Dowey, S.N.; Cheng, L. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 2011, 118, 4599-4608.
128. Zou, J.; Sweeney, C.L.; Chou, B.K.; Choi, U.; Pan, J.; Wang, H.; Dowey, S.N.; Cheng, L.; Malech, H.L. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: Functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 2011, 117, 5561-5572.
129. Sebastiano, V.; Maeder, M.L.; Angstman, J.F.; Haddad, B.; Khayter, C.; Yeo, D.T.; Goodwin, M.J.; Hawkins, J.S.; Ramirez, C.L.; Batista, L.F.; et al. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 2011, 29, 1717-1726.
130. Cathomen, T.; Schambach, A. Zinc-finger nucleases meet iPS cells: Zinc positive: tailored genome engineering meets reprogramming. Gene Ther. 2010, 17, 1-3.
131. Di Giorgio, F.P.; Boulting, G.L.; Bobrowicz, S.; Eggan, K.C. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell 2008, 3, 637-648.
132. Di Giorgio, F.P.; Carrasco, M.A.; Siao, M.C.; Maniatis, T.; Eggan, K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat. Neurosci. 2007, 10, 608-614.
133. Nagai, M.; Re, D.B.; Nagata, T.; Chalazonitis, A.; Jessell, T.M.; Wichterle, H.; Przedborski, S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 2007, 10, 615-622.
134. Hampton, D.W.; Webber, D.J.; Bilican, B.; Goedert, M.; Spillantini, M.G.; Chandran, S. Cell-mediated neuroprotection in a mouse model of human tauopathy. J. Neurosci. 2010, 30, 9973-9983.
135. Roy, N.S.; Cleren, C.; Singh, S.K.; Yang, L.; Beal, M.F.; Goldman, S.A. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat. Med. 2006, 12, 1259-1268.
136. Imaizumi, T.; Lankford, K.L.; Waxman, S.G.; Greer, C.A.; Kocsis, J.D. Transplanted olfactory ensheathing cells remyelinate and enhance axonal conduction in the demyelinated dorsal columns of the rat spinal cord. J. Neurosci. 1998, 18, 6176-6185.
137. Blakemore, W.F.; Crang, A.J. Extensive oligodendrocyte remyelination following injection of cultured central nervous system cells into demyelinating lesions in adult central nervous system. Dev. Neurosci. 1988, 10, 1-11.
138. Franklin, R.J.; Blakemore, W.F. Transplanting oligodendrocyte progenitors into the adult CNS. J. Anat. 1997, 190, 23-33.
139. Barnett, S.C.; Alexander, C.L.; Iwashita, Y.; Gilson, J.M.; Crowther, J.; Clark, L.; Dunn, L.T.; Papanastassiou, V.; Kennedy, P.G.; Franklin, R.J. Identification of a human olfactory ensheathing cell that can effect transplant-mediated remyelination of demyelinated CNS axons. Brain, 2000, 123, 1581-1588.
140. Brüstle, O.; Jones, K.N.; Learish, R.D.; Karram, K.; Choudhary, K.; Wiestler, O.D.; Duncan, I.D.; McKay, R.D. Embryonic stem cell-derived glial precursors: A source of myelinating transplants. Science 1999, 285, 754-756.
141. Keirstead, H.S.; Ben-Hur, T.; Rogister, B.; O'Leary, M.T.; Dubois-Dalcq, M.; Blakemore, W.F. Polysialylated neural cell adhesion molecule-positive CNS precursors generate both oligodendrocytes and Schwann cells to remyelinate the CNS after transplantation. J. Neurosci. 1999, 19, 7529-7536.
142. Kohama, I.; Lankford, K.L.; Preiningerova, J.; White, F.A.; Vollmer, T.L.; Kocsis, J.D. Transplantation of cryopreserved adult human Schwann cells enhances axonal conduction in demyelinated spinal cord. J. Neurosci. 2001, 21, 944-950.
143. Mitome, M.; Low, H.P.; van den Pol, A.; Nunnari, J.J.; Wolf, M.K.; Billings-Gagliardi, S.; Schwartz, W.J. Towards the reconstruction of central nervous system white matter using neural precursor cells. Brain 2001, 124, 2147-2161.
144. Akiyama, Y.; Radtke, C.; Kocsis, J.D. Remyelination of the rat spinal cord by transplantation of identified bone marrow stromal cells. J. Neurosci. 2002, 22, 6623-6630.
145. Feron, F.; Perry, C.; Cochrane, J.; Licina, P.; Nowitzke, A.; Urquhart, S.; Geraghty, T.; Mackay-Sim, A. Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain 2005, 128, 2951-2960.
146. Franklin, R.J.; Gilson, J.M.; Franceschini, I.A.; Barnett, S.C. Schwann cell-like myelination following transplantation of an olfactory bulb-ensheathing cell line into areas of demyelination in the adult CNS. Glia 1996, 17, 217-224.
147. Sasaki, M.; Lankford, K.L.; Zemedkun, M.; Kocsis, J.D. Identified olfactory ensheathing cells transplanted into the transected dorsal funiculus bridge the lesion and form myelin. J. Neurosci. 2004, 24, 8485-8493.
148. Lakatos, A.; Barnett, S.C.; Franklin, R.J. Olfactory ensheathing cells induce less host astrocyte response and chondroitin sulphate proteoglycan expression than Schwann cells following transplantation into adult CNS white matter. Exp. Neurol. 2003, 184, 237-246.
149. Lakatos, A.; Franklin, R.J.; Barnett, S.C. Olfactory ensheathing cells and Schwann cells differ in their in vitro interactions with astrocytes. Glia 2000, 32, 214-225.
150. Lassmann, H.; Bruck, W.; Lucchinetti, C. Heterogeneity of multiple sclerosis pathogenesis: Implications for diagnosis and therapy. Trends Mol. Med. 2001, 7, 115-121.
151. Lucchinetti, C.; Bruck, W. The pathology of primary progressive multiple sclerosis. Mult. Scler. 2004, 10, S23-S30.
152. Hammarberg, H.; Lidman, O.; Lundberg, C.; Eltayeb, S.Y.; Gielen, A.W.; Muhallab, S.; Svenningsson, A.; Lindå, H.; van Der Meide, P.H.; Cullheim, S.; et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J. Neurosci. 2000, 20, 5283-5291.
153. Foote, A.K.; Blakemore, W.F. Inflammation stimulates remyelination in areas of chronic demyelination. Brain 2005, 128, 528-539.
154. Joannides, A.J.; Webber, D.J.; Raineteau, O.; Kelly, C.; Irvine, K.A.; Watts, C.; Rosser, A.E.; Kemp, P.J.; Blakemore, W.F.; Compston, A.; et al. Environmental signals regulate lineage choice and temporal maturation of neural stem cells from human embryonic stem cells. Brain 2007, 130, 1263-1275.
155. Vana, A.C.; Flint, N.C.; Harwood, N.E.; Le, T.Q.; Fruttiger, M.; Armstrong, R.C. Platelet-derived growth factor promotes repair of chronically demyelinated white matter. J. Neuropathol. Exp. Neurol. 2007, 66, 975-988.
156. Armstrong, R.C.; Le, T.Q.; Flint, N.C.; Vana, A.C.; Zhou, Y.-X. Endogenous cell repair of chronic demyelination. J. Neuropathol. Exp. Neurol. 2006, 65, 245-256.
157. Connick, P.; Kolappan, M.; Crawley, C.; Webber, D.J.; Patani, R.; Michell, A.W.; Du, M.Q.; Luan, S.L.; Altmann, D.R.; Thompson, A.J.; et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. Lancet Neurol. 2012, 11, 150-156.